Patient treated at VCU Health
BOSTON, Feb. 25, 2025 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, announced today that the first patient has been randomized to and treated with the eShunt® System in its STRIDE clinical trial, a head-to-head comparison of the novel eShunt System versus the standard of care ventriculo-peritoneal (VP) shunt in patients with normal pressure hydrocephalus (NPH). The patient was treated at VCU Health in Richmond. Multiple trial site locations are now open across the United States.
STRIDE is a multi-center, randomized, controlled trial designed to assess the safety and efficacy of the eShunt System compared with the current standard of care, the VP shunt, in elderly patients diagnosed with NPH. The results of the STRIDE trial will serve as the basis for CereVasc’s anticipated Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA).
NPH is a life-threatening form of communicating hydrocephalus that affects 800,000 people in the United States alone.
“I was honored to perform the inaugural treatment in the STRIDE trial. This investigation could lead to a safer and less invasive way to address the gait disturbance, cognitive deficits, and urinary incontinence that are experienced by people with NPH,” said John Reavey-Cantwell, M.D., Neurosurgeon and Director of Cerebrovascular and Endovascular Neurosurgery at VCU Health. “Because the eShunt System is less invasive than the VP shunt, this trial will assess its potential to improve recovery times and reduce post-operative complications such as infection. As a result, I’m hopeful it will make treatment possible for more patients living with this devastating neurological disease — including those who have comorbidities.”
The eShunt System is the only endovascular shunt and the first new treatment option developed for NPH since the standard of care was introduced more than 60 years ago.
“The treatment of the first patient with the eShunt® System in the STRIDE trial marks an important milestone for CereVasc by providing a potential new treatment option for patients with NPH and for the medical community, which has expressed considerable enthusiasm about the promise of the eShunt System,” said Dan Levangie, CereVasc’s Chairman & CEO. “As the first randomized controlled trial comparing a modern alternative with the standard-of-care treatment for NPH, this trial is an important step in evaluating the safety and effectiveness of the eShunt System. This trial could provide a way for elderly patients with NPH to improve their quality of life while supporting an overall movement toward minimally invasive procedures across the field of neurosurgery.”
For more information, please visit https://nphstridestudy.com/.
About CereVasc, Inc.
Located in Massachusetts’ healthcare hub, CereVasc, Inc., is a clinical stage, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, encompasses first-ever, groundbreaking percutaneous transvenous-transdural access to the central nervous system intended to allow the first minimally invasive treatment for communicating hydrocephalus (CH). The eShunt device concept originated from Tufts Medical Center physicians Carl Heilman, MD, Neurosurgeon and Chair Emeritus of Neurosurgery, and Adel Malek, MD, PhD, Chief of Neurovascular Surgery and Director of Cerebrovascular and Endovascular Neurosurgery. The patented eShunt System includes an endovascularly implantable cerebral spinal fluid shunt and delivery components, which are designed to treat CH without invasive surgery. For additional information, please visit our website at www.cerevasc.com.
The eShunt® Device is an investigational device and has not been approved by FDA or any other regulatory agency for commercial sale. Its safety and effectiveness have not yet been fully established.
Company Contact:
DJ Cass
CereVasc, Inc.
Media Contacts:
Ethan Metelenis
Precision AQ
Ethan.Metelenis@precisionaq.com
Christina Renfroe
Precision AQ
Christina.Renfroe@precisionaq.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cerevasc-announces-first-patient-randomized-to-eshunt-system-treatment-in-stride-pivotal-trial-302383771.html
SOURCE CereVasc
